Bonus BioGroup Ltd
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of… Read more
Bonus BioGroup Ltd (BBIXF) - Total Assets
Latest total assets as of June 2025: $17.33 Million USD
Based on the latest financial reports, Bonus BioGroup Ltd (BBIXF) holds total assets worth $17.33 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bonus BioGroup Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Bonus BioGroup Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bonus BioGroup Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Bonus BioGroup Ltd's total assets of $17.33 Million consist of 30.7% current assets and 69.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Bonus BioGroup Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bonus BioGroup Ltd's current assets represent 30.7% of total assets in 2024, a decrease from 81.6% in 2013.
- Cash Position: Cash and equivalents constituted 29.3% of total assets in 2024, up from 9.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 0.0% of total assets.
Bonus BioGroup Ltd Competitors by Total Assets
Key competitors of Bonus BioGroup Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Bonus BioGroup Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bonus BioGroup Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bonus BioGroup Ltd is currently not profitable relative to its asset base.
Bonus BioGroup Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.21 | 1.95 | 0.15 |
| Quick Ratio | 0.21 | 1.95 | 0.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.78 Million | $ 7.11 Million | $ -16.05 Million |
Bonus BioGroup Ltd - Advanced Valuation Insights
This section examines the relationship between Bonus BioGroup Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.75 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | -47.9% |
| Total Assets | $23.41 Million |
| Market Capitalization | $10.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bonus BioGroup Ltd's assets below their book value (0.44 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bonus BioGroup Ltd's assets decreased by 47.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bonus BioGroup Ltd (2013–2024)
The table below shows the annual total assets of Bonus BioGroup Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $23.41 Million | -47.86% |
| 2023-12-31 | $44.89 Million | -39.84% |
| 2022-12-31 | $74.61 Million | -28.48% |
| 2021-12-31 | $104.32 Million | +102.82% |
| 2020-12-31 | $51.44 Million | +635.87% |
| 2019-12-31 | $6.99 Million | -31.19% |
| 2018-12-31 | $10.16 Million | +82.14% |
| 2017-12-31 | $5.58 Million | +92.58% |
| 2016-12-31 | $2.90 Million | -49.69% |
| 2015-12-31 | $5.76 Million | +27.26% |
| 2014-12-31 | $4.52 Million | -44.55% |
| 2013-12-31 | $8.16 Million | -- |